Archives
-
Trichostatin A and the HDAC3–Ferroptosis Axis
2026-10-01
Trichostatin A (TSA) offers a practical route to interrogate how histone deacetylase activity shapes cancer-cell state. This thought-leadership article connects TSA-based epigenetic perturbation with the HDAC3–NRF2–GPX4 ferroptosis axis in colorectal cancer, while outlining controls, protocol considerations, translational limits, and opportunities for better mechanistic validation.
-
AZD3463: ALK/IGF1R Inhibitor for Neuroblastoma
2026-09-30
AZD3463 is an orally bioavailable ALK/IGF1R inhibitor investigated in preclinical ALK-driven cancer research. Reported activity includes inhibition of wild-type and mutant ALK, ALK-mediated PI3K/AKT/mTOR pathway inhibition, neuroblastoma apoptosis induction, and tumor-growth reduction in orthotopic mouse models.
-
LY294002: PI3K/Akt/mTOR Assay Workflows
2026-09-30
Build reproducible PI3K/Akt/mTOR, macrophage-polarization, apoptosis, and autophagy assays with LY294002 while accounting for reversibility and micromolar off-target activity. This workflow translates an allergic-asthma signaling study into practical cell-based experiments without overstating what the reference study directly demonstrated.
-
KU-60019: Strategic ATM Inhibition in Glioma
2026-09-29
A translational framework for using KU-60019 as a selective ATM kinase inhibitor, with emphasis on glioma radiosensitization, invasion biology, experimental controls, metabolic context, and evidence-based development strategy.
-
NU7441 (KU-57788) DNA-PK Inhibitor Guide
2026-09-29
NU7441, also called KU-57788, is an ATP-competitive DNA-PK inhibitor with a reported DNA-PK IC50 of approximately 13–14 nM. This guide separates product-reported potency and workflow parameters from peer-reviewed evidence on DNA damage response, telomere maintenance, and oncology research.
-
MG-132 (Z-LLL-al) Workflow for Proteasome Studies
2026-09-28
MG-132 (Z-LLL-al) provides a fast, cell-permeable way to connect proteasome blockade with protein accumulation, apoptosis, oxidative stress, and cell-cycle phenotypes. This practical guide translates the FGF19–TRIM21–ANXA2 findings in nasopharyngeal carcinoma into assay designs, controls, and troubleshooting steps for cancer research.
-
KU-60019: ATM Kinase Inhibitor for Glioma Research
2026-09-28
KU-60019 is a potent ATM kinase inhibitor used to investigate DNA damage response signaling and glioma radiosensitization. Product information reports selective ATM inhibition and glioma-cell effects, while a separate study links ATM inhibition to macropinocytosis in other cancer models.
-
Cy3 Goat Anti-Human IgG (H+L): Signal to Inference
2026-09-27
The Cy3 Goat Anti-Human IgG (H+L) Antibody supports fluorescent detection of human IgG, but choosing the right detection reagent also depends on species, assay purpose, and biological interpretation. Using recent orthopoxvirus antibody research as a case study, this article explains where a Cy3 conjugated secondary antibody fits—and where it does not.
-
Lamotrigine B2249: Reliable Cell Assay Design
2026-09-26
A practical, evidence-led guide to using Lamotrigine (SKU B2249) in viability, proliferation, and cytotoxicity workflows without confusing assay interference with biological effects. Covers mechanism-aware controls, stock preparation, interpretation limits, and product selection.
-
Meropenem Trihydrate for Resistance Phenotyping
2026-09-25
Meropenem trihydrate is a carbapenem antibiotic useful for studying bacterial susceptibility and resistance. This article explains how to pair its controlled use with antibiotic-free metabolomic profiling while keeping baseline resistance signatures distinct from drug-response effects.
-
5-Aminolevulinic acid HCl in Heme Pathway Assays
2026-09-25
Use 5-Aminolevulinic acid HCl as a defined pathway-entry perturbation—not as a substitute for heme—to test how tetrapyrrole flux relates to Salmonella phagocytosis resistance. The same precursor also supports distinct cancer research workflows involving protoporphyrin IX, photodynamic therapy, and fluorescence-guided tumor resection.
-
Beyond DNA Repair: NU7441 in Translational Research
2026-09-24
NU7441 (KU-57788) offers researchers a selective way to interrogate DNA-PK in DNA repair and oncology studies. This article connects its established experimental use with emerging findings on cytosolic DNA and TDP-43, while distinguishing evidence from hypotheses and outlining practical validation strategies.
-
CD28–ARS2 Control of PKM Splicing in CD8+ T Cells
2026-09-24
The study identifies a CD28–ARS2 signaling axis that reshapes alternative splicing in activated CD8+ T cells, favoring PKM2 over PKM1 and supporting glucose-use flexibility, IFNγ production, and antitumor function. It links costimulatory signaling to RNA processing through a mechanism reported to operate independently of CD28-driven PI3K activation, while highlighting the need to measure metabolic and immune outcomes together.
-
ATM Inhibition Triggers Macropinocytosis in Cancer Cells
2026-09-23
Huang and colleagues show that ATM suppression can promote macropinocytosis, helping cancer cells obtain nutrients and survive in nutrient-poor conditions. Their findings connect ATM-dependent metabolic adaptation to amino acid availability and identify macropinocytosis as a potential vulnerability, while leaving important questions about tumor context and therapeutic translation open.
-
Meropenem trihydrate: 5 Lab Scenarios
2026-09-23
This scenario-based guide explains how Meropenem trihydrate, SKU B1217, can support controlled bacterial challenge, resistance phenotyping, and cell-based assay interpretation. It combines product handling information with recent metabolomics evidence to help researchers improve experimental consistency without overstating cross-system validation.